TheraRadar
Clinical-Stage Companies / Sangamo

Sangamo

Pre-Approval PRO BETA
17
Total Trials
0
Phase 3
15
Phase 2
2
Recruiting
164
Score

Pipeline by Phase

Phase 3
Phase 2
15
Phase 1
13

Therapeutic Focus

Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetic Polyneuropathy HIV HIV Infection

Clinical Trials (17)

NCT01079325 Phase 2 COMPLETED

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Started: 11/1/2009

NCT00876863 Phase 2 COMPLETED

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Started: 11/1/2008

NCT00748501 Phase 2 COMPLETED

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Started: 9/1/2008

NCT00665145 Phase 2 COMPLETED

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

Started: 1/1/2008

NCT06980948 Phase 1 RECRUITING

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Started: 12/4/2025

NCT04046224 Phase 1 COMPLETED

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

Started: 7/23/2019

NCT03653247 Phase 1 COMPLETED

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Started: 3/6/2019

NCT04817774 Phase 1 ACTIVE NOT RECRUITING

Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients

Started: 3/17/2021

NCT02695160 Phase 1 TERMINATED

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Started: 11/15/2016

NCT03432364 Phase 1 COMPLETED

A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

Started: 3/29/2018

NCT02702115 Phase 1 TERMINATED

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

Started: 5/24/2017

NCT03041324 Phase 1 TERMINATED

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Started: 5/11/2017

NCT01543152 Phase 1 COMPLETED

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

Started: 12/1/2011

NCT02225665 Phase 1 COMPLETED

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Started: 8/1/2014

NCT00985517 Phase 1 COMPLETED

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

Started: 10/29/2009

NCT01252641 Phase 1 COMPLETED

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Started: 11/1/2010

NCT01044654 Phase 1 COMPLETED

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Started: 12/1/2009

Drug Candidates

ST-920 Plerixafor Busulfan TX200-TR101 SB-FIX SB-318 SB-913 SB-509 Cyclophosphamide CERE-110: Adeno-Associated Virus injection Surgery
Activity Status: Active
Last Trial Started: 12/4/2025
Last Trial Ended: 7/17/2025
Trials (12 months): 1
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.